Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
NCT07404865 · UPSTREAM SjD Phase 3Recruiting
- Lead sponsor
- Vor Biopharma (Industry)
- Enrollment
- 250 (estimated)
- Start date
- 26 Feb 2026
- Primary completion
- Dec 2028 (estimated)
- Study completion
- 1 Jan 2029
- Last update posted
- 19 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 2
Interventions
- Telitacicept Biological
- Placebo Drug
Conditions and primary outcome
- Primary Sjogren's Disease
Primary outcome
To evaluate the efficacy of telitacicept versus placebo at Week 48 in the change from baseline in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score at Week 48. (Week 48)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07404865.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07404865 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.